Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.
- January 2026 — CDMO Opportunities And Threats Report
- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2215842261-lab-scientist-looking-down-research]( "Formulation Development Of Enterically Protected Spray Dried Dispersions")
Formulation Development Of Enterically Protected Spray Dried DispersionsAdrulipase spray-dried dispersions were evaluated to create an orally delivered, enteric-protected enzyme. The lead formulation provided the best acid protection, rapid release, and stability.
-
![GettyImages-2165446110 lab, flow cytometry, research]( "A Toolkit For Unraveling Protein Expression Patterns")
A Toolkit For Unraveling Protein Expression PatternsLearn about a method that utilizes monoclonal antibodies and flow cytometry to analyze the metabolic state of individual immune cells, advancing immune research and immunotherapy.
-
![GettyImages-1480558197 Business Corporate Team Meeting]( "Enabling Market Access As CGTs Reach More Patients")
Enabling Market Access As CGTs Reach More PatientsBringing potentially curative cell and gene therapies to more patients requires a focused approach to market access. Discover essential insights into payer dynamics, pricing innovations, and treatment evolution.
-
![GettyImages-2182054861-mab-process-capture-3d-close-up]( "Balancing Protein A Resin Cost, Performance, And Productivity")
Balancing Protein A Resin Cost, Performance, And ProductivityOptimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
![GettyImages-2193840525-dna-strand-viral-vector-gene-therapy]( "Advanced Sequencing Approaches For Comprehensive AAV Vector Characterization")
Advanced Sequencing Approaches For Comprehensive AAV Vector CharacterizationShort and long read sequencing offer complementary insights into AAV vector identity, integrity, and impurity profiles, helping developers improve safety, efficacy, and scalability of gene therapy products.
-
![GettyImages-597972428-adenovirus]( "Development Strategies For Adenovirus-Based Gene Therapies")
Development Strategies For Adenovirus-Based Gene TherapiesScaling up viral vector production can be challenging, and ensuring consistent titers and activity requires careful optimization and technical expertise.
-
![GettyImages-1221576332 cell therapy]( "Understanding Potency In Gene Therapy Development")
Understanding Potency In Gene Therapy DevelopmentExplore the importance of understanding potency in cell and gene therapy (CGT) development and the challenges in developing potency assays for CGT products.
-
![CHOgro® High Yield Expression System]( "High Yield Protein Production System For Suspension CHO Cells")
High Yield Protein Production System For Suspension CHO CellsReduced the risk of contamination caused by repeated handling of the culture during transient protein production in suspension CHO cells.
-
![GettyImages-500323894 research tech]( "Advances In Flow-Through Technology To Enhance mAb Polishing")
Advances In Flow-Through Technology To Enhance mAb PolishingOptimize your monoclonal antibody purification with cutting-edge flow-through chromatography. Learn how POROS resins enhance polishing efficiency, improve aggregate removal, and streamline bioprocessing.
-
![GettyImages-1472832232 cleanroom]( "Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy")
Activate Advanced Contamination Control Technology To Safeguard Your Cell TherapyThe most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.
NEWSLETTER ARCHIVE
- 02.18.26 -- Specialized Fill/Finish For Advanced Therapies
- 02.18.26 -- Cold-Chain Packaging Strategies For Scaling Gene Therapies
- 02.18.26 -- Building Safer CRISPR Medicines For CVD With Benjamin Oakes
- 02.17.26 -- STREAM Edition: Introducing mRNA Hot Takes, A New Video Series From Advancing RNA
- 02.17.26 -- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
